FreeTheAI

Zentalis Pharmaceuticals Reports Interim Overall Survival Data for Ovarian Cancer Drug Azenosertib

BullishMedium impact
ZNTL$2.13 −4.91%

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) released overall survival data from an interim analysis of its Phase 1b DENALI trial evaluating azenosertib in patients with platinum-resistant ovarian cancer. Patients in the Cyclin E1-positive subgroup achieved a median overall survival of 15.8 months, compared with 7.5 months for those in the Cyclin E1-negative subgroup. The study found no new safety issues, and results were published ahead of an upcoming presentation at the European Society for Medical Oncology Congress 2026.

The trial results indicate that Cyclin E1 expression serves as a predictive biomarker for patient response to azenosertib, an investigational oral WEE1 inhibitor. In biomarker-positive patients, the median overall survival compared favorably against historical benchmarks for single-agent chemotherapy. Approximately half of all platinum-resistant ovarian cancer patients express Cyclin E1 protein, a group currently lacking targeted treatment options.

Investors and healthcare specialists will look to the full rapid oral presentation scheduled for October 23, 2026. Zentalis Pharmaceuticals is advancing azenosertib in its ongoing DENALI Part 2 trial aimed at potential accelerated approval, as well as a Phase 3 confirmatory trial named ASPENOVA designed to evaluate full regulatory approval against standard chemotherapy treatments.

Key points

  • Zentalis Pharmaceuticals reported interim Phase 1b trial data for azenosertib in platinum-resistant ovarian cancer.
  • Patients positive for the Cyclin E1 biomarker achieved median overall survival of 15.8 months versus 7.5 months for negative patients.
  • No new safety signals were identified during the interim analysis cutoff as of September 2025.
  • Results support ongoing Part 2 DENALI trials and a Phase 3 confirmatory study named ASPENOVA.

Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org

How we writeDisclaimer

Questions and answers

What were the DENALI Part 1b survival results for Zentalis Pharmaceuticals?

In the Cyclin E1-positive subgroup, patients treated with azenosertib reached a median overall survival of 15.8 months, compared to 7.5 months for the Cyclin E1-negative subgroup. No new safety signals were reported.

What is the next clinical step for azenosertib in ovarian cancer?

Zentalis is advancing azenosertib in the DENALI Part 2 study to support potential accelerated approval and conducting a Phase 3 trial, ASPENOVA, comparing azenosertib monotherapy to standard single-agent chemotherapy.